Skip to main content

Table 1 TrueSight Tumor 15 panel—Target genes NGS investigated for secondary resistance alterations after long-term treatment with cetuximab in DU145 and A431 cells

From: Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145

TruSight® Tumor 15
Gene
Target of Region
AKT1 E17K
BRAF V600E/K/R/M
EGFR Focal Amplification, Exon 19, Exon 20, G719A, Exon 21 (L858R), L861Q, S7681, T790M
ERBB2 Focal Amplification, p.E770_A771insAYVM (equivalent to p.A775_G776insYVMA)
FOXL2 C134W
GNA11 Q209L
GNAQ Q209L
KIT Exons 8,9,10,11,13,14,17,18
KRAS Codons 12,13,59,61,117,146
MET Focal Amplification
NRAS Codons 12,13,59,61,117,146
PDGFRA Exons 12,14,18
PIK3CA Exons 9,20
RET M918T
TP53 Full CDS